>
Switch to:

PTC Therapeutics Equity-to-Asset

: 0.05 (As of Sep. 2021)
View and export this data going back to 2013. Start your Free Trial

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. PTC Therapeutics's Total Stockholders Equity for the quarter that ended in Sep. 2021 was $104.9 Mil. PTC Therapeutics's Total Assets for the quarter that ended in Sep. 2021 was $2,007.3 Mil. Therefore, PTC Therapeutics's Equity to Asset Ratio for the quarter that ended in Sep. 2021 was 0.05.

The historical rank and industry rank for PTC Therapeutics's Equity-to-Asset or its related term are showing as below:

NAS:PTCT' s Equity-to-Asset Range Over the Past 10 Years
Min: -5.41   Med: 0.41   Max: 0.96
Current: 0.05

-5.41
0.96

During the past 10 years, the highest Equity to Asset Ratio of PTC Therapeutics was 0.96. The lowest was -5.41. And the median was 0.41.

NAS:PTCT's Equity-to-Asset is ranked lower than
89% of the 1513 Companies
in the Biotechnology industry.

( Industry Median: 0.76 vs. NAS:PTCT: 0.05 )

PTC Therapeutics Equity-to-Asset Historical Data

The historical data trend for PTC Therapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PTC Therapeutics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Equity-to-Asset
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.44 0.40 0.31 0.37 0.22

PTC Therapeutics Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
Equity-to-Asset Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.23 0.22 0.14 0.10 0.05

Competitive Comparison

For the Biotechnology subindustry, PTC Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

PTC Therapeutics Equity-to-Asset Distribution

For the Biotechnology industry and Healthcare sector, PTC Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where PTC Therapeutics's Equity-to-Asset falls into.



PTC Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

PTC Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2020 is calculated as

Equity to Asset (A: Dec. 2020 )=Total Stockholders Equity/Total Assets
=481.982/2208.278
=0.22

PTC Therapeutics's Equity to Asset Ratio for the quarter that ended in Sep. 2021 is calculated as

Equity to Asset (Q: Sep. 2021 )=Total Stockholders Equity/Total Assets
=104.926/2007.325
=0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PTC Therapeutics  (NAS:PTCT) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


PTC Therapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of PTC Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


PTC Therapeutics Business Description

PTC Therapeutics logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Traded in Other Exchanges
Address
100 Corporate Court, South Plainfield, NJ, USA, 07080
PTC Therapeutics Inc is a global biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when a RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.
Executives
Southwell David P director C/O INOTEK PHARMACEUTICALS CORPORATION 91 HARTWELL AVENUE LEXINGTON MA 02421
Jacobson Allan Steven director PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Peltz Stuart Walter director, officer: Chief Executive Officer PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Utter Christine Marie officer: SVP, Finance & CAO C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Boulding Mark Elliott officer: Exec. VP and CLO C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Hill Emily Luisa officer: Chief Financial Officer C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Svoronos Dawn director C/O MEDIVATION, INC. 525 MARKET ST., 36TH FLOOR SAN FRANCISCO CA 94105
Pauwels Eric officer: Chief Business Officer 550 HILLS DRIVE BEDMINSTER NJ 07921
Klein Matthew B. officer: Chief Development Officer C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Schmertzler Michael director 1300 VALLEY ROAD NEW CANAAN CT 06840
Souza Marcio officer: Chief Operating Officer C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Almstead Neil Gregory officer: Chief Technical Ops Officer C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Reeve Emma director C/O PAREXEL INTERNATIONAL CORPORATION 195 WEST STREET WALTHAM MA 02451
Steele Glenn Jr Md Phd director 250 TECHNOLOGY PARK LAKE MARY FL 32746-6232
Zeldis Jerome B director 8767 E. VIA DE VENTURA, SUITE 190 SCOTTSDALE AZ 85258

PTC Therapeutics Headlines

Other Sources

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)